Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Examining Opioid-Related Hospitalizations for Patients With Cancer

April 2, 2019
By Leah Lawrence
Article

Researchers looked at the trends and risk factors for opioid-related hospitalizations among patients with cancer.

Patients with cancer were rarely hospitalized for opioid-related reasons, according to a study published recently in JAMA Oncology. Although rates are increasing at a low rate over time, most of the hospitalizations are associated with non-heroin opioid poisoning, the study showed.

“In light of the wider opioid epidemic, oncologists and palliative care clinicians frequently balance providing patients with legitimate access to opioids while protecting them and the general public from the risks associated with prescribing these medications,” wrote Isaac S. Chua, MD, of Dana-Farber Cancer Institute, and colleagues in a research letter.

Chua and colleagues looked at the trends and risk factors for opioid-related hospitalizations among patients with cancer between 2006 and 2014 using data from the US National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP). The primary outcome was opioid-related hospitalizations among adults age 18 or older.

Of the more than 25 million hospitalizations for patients with cancer, only 0.06% were related to opioids. From 2006 to 2014, the average number of opioid-related hospitalizations increased to 78.9 admissions per year (P = .01).

The majority of hospitalizations were non-heroin related (88.0%). The researchers identified several factors associated with opioid-related hospitalizations for patients with cancer, such as drug abuse (odds ratio [OR], 7.92; 95% CI, 6.95–9.02), depression (OR, 2.34; 95% CI, 2.13–2.58), psychotic disorder (OR, 4.13; 95% CI, 3.66–4.65), white race, younger age, and year of hospitalization.

“Prior to prescribing opioids for cancer-related pain, routinely screening patients using standardized tools based on these associated factors (eg, Opioid Risk Tool) may identify those patients with the greatest risk of an opioid-related hospitalization,” the researchers wrote. “Additional research on opioid risk screening and management for patients with combined cancer and substance use disorders is needed.”

Jon Mark Hirshon, MD, PhD, MPH, professor in the department of emergency medicine at the University of Maryland School of Science, told Cancer Network that these types of studies are important because “the issue of opioid misuse and abuse remains a significant and troubling societal problem causing widespread morbidity and mortality.”

“As a practicing emergency physician in inner-city Baltimore, I see this problem multiple times every shift. However, as noted within the article, the impact of this problem among patients with cancer is quite rare (0.06% of admissions) and has a very low rate of increase,” Hirshon said. “There are some weaknesses to the research, as it may underestimate the rate of the problem because it is based solely upon the primary diagnosis field and may have missed the diagnosis if placed in a secondary field. However, in the end, the article does not significantly impact clinical practice of emergency medicine and the need to remain vigilant both to the pain treatment needs of patients with cancer, as well as the continuing scourge of opioid misuse and abuse regardless of the patient population.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Kyle Doherty
July 11th 2025
Article

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Tim Cortese
July 11th 2025
Article

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


For the First Time, A Nilotinib Without Fasting Restrictions

For the First Time, A Nilotinib Without Fasting Restrictions

July 11th 2025
Article

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC

Russ Conroy
July 11th 2025
Article

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Related Content

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Kyle Doherty
July 11th 2025
Article

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Tim Cortese
July 11th 2025
Article

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


For the First Time, A Nilotinib Without Fasting Restrictions

For the First Time, A Nilotinib Without Fasting Restrictions

July 11th 2025
Article

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC

Russ Conroy
July 11th 2025
Article

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.